Aktienanalyse zu Stereotaxis Inc (STXS)STXSStereotaxis Inc

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Currently, Stereotaxis Inc. (STXS) is trading at $0.8801, which is significantly below its 52-week high of $2.89, indicating a potential undervaluation. However, the stock has shown a year-to-date change of -62.06%, reflecting ongoing challenges. The RSI is at 24.233, suggesting the stock is oversold, but this could also indicate continued weakness. The forward P/E ratio is at 19.6464, which is relatively high given the company's recent performance. The main risk is the net loss of $4.78 million reported in Q2 2026, widening from a loss of $4.14 million year-over-year, which raises concerns about financial stability. Therefore, while there are potential upside opportunities, the current financial instability and market sentiment suggest holding rather than buying at this time.

1 analysts cover STXS: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.20.